drugset / Trial / NCT07283692
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
NaSingle-groupOpen-labelTreatment
Summary
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
Timeline
- Start
- 2026-03-01
- Primary completion
- 2026-12
- Completion
- 2031-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Subject | Serplulimab | Monoclonal antibody | 1.5 mg/kg | — |